FT vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FT exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative balance sheet (Debt/Equity 0.29). The stock is significantly undervalued, trading at $8.14, which is well below both its Graham Number ($12.11) and estimated Intrinsic Value ($22.71). While the technical trend is bearish and revenue has contracted by 27.1%, the combination of a low P/E (10.57), a P/B under 1.0, and a sustainable 6.27% dividend yield makes it a compelling value play.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
FT vs JPM: Head-to-Head Comparison
This page compares Franklin Universal Trust (FT) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.